Health economic evaluation of introducing a PPSV23-based vaccination programme to adults aged 65 and above, and an extension to the 60-64 age group in Denmark. (3rd October 2021)

• Record Type: Journal Article
• Authors: Birck, Anders Muusfeldt; Nordin Christensen, Liv; Pedersen, Mikkel H.; Olsen, Jens; Johnson, Kelly D.; Bencina, Goran; Clausen, Thomas Holtkøtter; Larsen, Carsten Schade
• Is Part Of: Expert review of vaccines. Volume 20:Number 10(2021)
• Page Start: 1327
• Page End: 1337
• Publication Date: 2021-10-03
• Subjects: Costs -- cost-effectiveness -- PPSV23 -- pneumococcal disease -- vaccination programme -- vaccine; Vaccines -- Periodicals; Vaccination -- Periodicals; 615.37205
• DOI: 10.1080/14760584.2021.1977627
• Languages: English
• ISSNs: 1476-0584

Abstract

ABSTRACT: Background: To estimate the health economic consequences of the recently introduced PPSV23 vaccination programme for persons aged 65+ in Denmark and of a potential extension of the programme to include persons aged 60–64 years. Research design and methods: A Markov model was adapted to the Danish healthcare setting to simulate the epidemiological and economic burden of invasive pneumococcal disease and non-bacteremic pneumococcal pneumonia using information from published sources and Danish databases. Results: We found that the recent introduction of an age-based vaccination programme offering PPSV23 vaccination to the population of persons aged 65+ in Denmark will lead to a societal gain of EUR 72.0 million and prevent 19, 707 cases of pneumococcal disease and 1, 308 deaths per 1 million persons during the five-year study period. Similarly, we estimate that extending the programme to include persons aged 60–64 will lead to a gain of EUR 14.6 million per 1 million persons and prevent an additional 6, 223 cases of pneumococcal disease and 185 deaths. Conclusion: The recent introduction of the age-based vaccination programme offering PPSV23 vaccination to all persons aged 65+ in Denmark is cost-effective. This is also the case if the programme is extended to include persons aged 60–64.